Seeyond boosted its position in shares of DaVita Inc. (NYSE:DVA) by 0.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 21,876 shares of the company’s stock after purchasing an additional 98 shares during the period. Seeyond’s holdings in DaVita were worth $2,634,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the business. Parisi Gray Wealth Management acquired a new stake in DaVita during the second quarter worth about $50,000. LPL Financial LLC grew its stake in DaVita by 39.0% during the second quarter. LPL Financial LLC now owns 16,571 shares of the company’s stock worth $1,996,000 after buying an additional 4,651 shares in the last quarter. Bridgewater Associates LP acquired a new stake in DaVita during the second quarter worth about $4,042,000. Toronto Dominion Bank grew its stake in DaVita by 455.5% during the second quarter. Toronto Dominion Bank now owns 200,324 shares of the company’s stock worth $24,125,000 after buying an additional 164,264 shares in the last quarter. Finally, AXA S.A. boosted its stake in shares of DaVita by 789.6% in the 2nd quarter. AXA S.A. now owns 52,727 shares of the company’s stock valued at $6,350,000 after purchasing an additional 46,800 shares in the last quarter. Hedge funds and other institutional investors own 86.52% of the company’s stock.
DaVita stock traded up $1.01 during mid-day trading on Thursday, hitting $110.97. 8,555 shares of the stock were exchanged, compared to its average volume of 682,472. The company has a quick ratio of 1.62, a current ratio of 1.67 and a debt-to-equity ratio of 6.01. DaVita Inc. has a 12 month low of $84.14 and a 12 month high of $136.48. The firm’s fifty day simple moving average is $125.17 and its two-hundred day simple moving average is $120.99. The stock has a market capitalization of $11.63 billion, a price-to-earnings ratio of 14.64, a PEG ratio of 1.00 and a beta of 1.28.
A number of equities research analysts have recently weighed in on DVA shares. Truist reduced their price target on shares of DaVita from $145.00 to $125.00 and set a “hold” rating on the stock in a research note on Wednesday. Cowen started coverage on shares of DaVita in a research note on Thursday, September 9th. They issued a “market perform” rating and a $145.00 price target on the stock. Barclays restated an “equal weight” rating and issued a $146.00 price target (up from $135.00) on shares of DaVita in a research note on Thursday, August 12th. William Blair restated a “market perform” rating on shares of DaVita in a research note on Wednesday, August 4th. Finally, Truist Securities cut their target price on shares of DaVita from $145.00 to $125.00 and set a “hold” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $140.43.
In other news, Director Pamela M. Arway sold 365 shares of DaVita stock in a transaction on Monday, August 23rd. The shares were sold at an average price of $133.09, for a total value of $48,577.85. Following the completion of the sale, the director now owns 19,239 shares in the company, valued at approximately $2,560,518.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paula A. Price sold 790 shares of DaVita stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $132.66, for a total transaction of $104,801.40. Following the completion of the sale, the director now owns 380 shares of the company’s stock, valued at approximately $50,410.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,915 shares of company stock valued at $5,113,533. Company insiders own 0.69% of the company’s stock.
DaVita Company Profile
DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.
Read More: Yield Curve
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.